SCHEMBL1640422

SCHEMBL1640422

Nc1cccc(-c2ncsc2-c2ccnc(Cl)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 1/20 0.42
TSHR P16473 1/20 0.39
RECQL P46063 1/20 0.39
PLK1 P53350 1/20 0.38
TGFBR1 P36897 1/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 3/20 0.36
CDK5 Q00535 2/20 0.36
CDK5R1 Q15078 2/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.35
LMNA P02545 2/20 0.35
MAP4K4 O95819 2/20 0.35
HPGD P15428 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13816258 0.82 RORB (0.33) TGFBR1KDM4E
SCHEMBL1641824 0.82 TGFBR1 (0.55) CAMK2DTSHRRECQLPLK1TGFBR1
SCHEMBL1641735 0.81 L3MBTL1 (0.42) CAMK2DTSHRRECQLPLK1NPC1
SCHEMBL1466904 0.80 CAMK2D (0.58) CAMK2DTSHRRECQLPLK1NPC1
SCHEMBL1642029 0.80 CDK2 (0.48) CAMK2DTSHRRECQLPLK1TGFBR1
SCHEMBL1641885 0.80 PDE4D (0.48) PLK1NPC1RAB9AMEN1KMT2A
SCHEMBL1127281 0.77 BRAF (0.51) CAMK2DTGFBR1EGFRCDK2CDK4
SCHEMBL31111793 0.75 KMO (0.33) TGFBR1CDK5ABL1CDK2CDK4
SCHEMBL3434367 0.75 JAK2 (0.35) CDK5LMNAPRKACACDK2DYRK3
SCHEMBL1494487 0.74 IDO1 (0.47) CAMK2DTSHRRECQLPLK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2231625-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 CAMK2D 328/4885TSHR 1129/4885RECQL 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.